These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 29277796)

  • 1. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
    Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
    Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH.
    Grin A; Brezden-Masley C; Bauer S; Streutker CJ
    Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):561-6. PubMed ID: 23455182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
    Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
    Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
    Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
    Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma.
    Subasinghe D; Acott N; Kumarasinghe MP
    Gastrointest Endosc; 2019 Jul; 90(1):44-54. PubMed ID: 30928424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
    Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
    Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
    Shan L; Ying J; Lu N
    Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
    Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
    Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
    Nadaf AS; Rani H; Dinesh US
    Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens.
    Fazlollahi L; Remotti HE; Iuga A; Yang HM; Lagana SM; Sepulveda AR
    Arch Pathol Lab Med; 2018 Apr; 142(4):516-522. PubMed ID: 28782986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma.
    Madani SH; Rahmati A; Sadeghi E; Khazaei S; Sadeghi M; Payandeh M; Amirifard N
    Asian Pac J Cancer Prev; 2015; 16(17):7755-8. PubMed ID: 26625793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
    Kunz PL; Mojtahed A; Fisher GA; Ford JM; Chang DT; Balise RR; Bangs CD; Cherry AM; Pai RK
    Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):13-24. PubMed ID: 21617522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
    Cinar P; Calkins SM; Venook AP; Kelley RK
    Anticancer Res; 2014 Dec; 34(12):7357-60. PubMed ID: 25503172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
    Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
    Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.
    Koopman T; Louwen M; Hage M; Smits MM; Imholz AL
    Am J Clin Pathol; 2015 Feb; 143(2):257-64. PubMed ID: 25596252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
    Fox SB; Kumarasinghe MP; Armes JE; Bilous M; Cummings MC; Farshid G; Fitzpatrick N; Francis GD; McCloud PI; Raymond W; Morey A
    Am J Surg Pathol; 2012 Apr; 36(4):577-82. PubMed ID: 22314190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.
    Janjigian YY; Werner D; Pauligk C; Steinmetz K; Kelsen DP; Jäger E; Altmannsberger HM; Robinson E; Tafe LJ; Tang LH; Shah MA; Al-Batran SE
    Ann Oncol; 2012 Oct; 23(10):2656-2662. PubMed ID: 22689179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.